Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240120 | PMC |
| http://dx.doi.org/10.1016/j.lrr.2025.100523 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis.
Future Sci OA
December 2025
Department of Obstetrics and Gynecology, Maternal and Child Health Hospital of Hunan Province, Changsha, China.
Objective: This study evaluated the benefits of immune checkpoint inhibitors (ICIs) and/or targeted therapies in mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) patients with advanced or recurrent endometrial cancer (EC) via network meta-analysis.
Methods: English databases were searched from inception through January 2025. Randomized controlled trials (RCTs) assessing the efficacy and safety of related therapies for patients with EC stratified by MMR status were included.
Isolated relapse of multiple myeloma in the central nervous system post autologous hematopoietic stem cell transplantation: a case report and literature review.
Front Oncol
July 2025
Department of Pathology, Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu, China.
This case report retrospectively evaluated the diagnosis and treatment of a multiple myeloma (MM) patient with early relapse in the central nervous system (CNS) post autologous hematopoietic stem cell transplantation (AHSCT). We also performed a literature review of treatment options for patients with CNS myeloma. The patient was diagnosed with isolated CNS relapse of multiple myeloma one month after AHSCT, without other extramedullary lesions and with normal blood, urine, and bone marrow profiles.
View Article and Find Full Text PDFCombined Inhibition of XPO1 and DNA Methylation Exerts Synergistic Effects in DLBCL.
Mol Carcinog
July 2025
Department of Hematology, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma characterized by high rates of relapse and limited responsiveness to standard chemotherapy. Selinxor, a selective inhibitor of XPO1, exhibited antitumor activity in various cancers. However, clinical trial results revealed that selinexor monotherapy exhibited unsatisfactory efficacy in DLBCL.
View Article and Find Full Text PDFHighlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.
Curr Hematol Malig Rep
July 2025
Levine Cancer Institute, Cancer Programs, Atrium Health, Wake Forest University School of Medicine, Charlotte, NC, USA.
Purpose Of Review: This report summarizes key insights from the 8th Annual International Symposium on Myeloproliferative Neoplasms (MPN Asia 2025). The symposium brought together global experts to discuss advancements in MPN biology, diagnostics, and therapeutics, with a focus on emerging molecular understanding, novel treatment strategies and real-world data.
Recent Findings: Molecular profiling has become essential in MPN risk stratification and therapeutic decision-making.
Selinexor combination with decitabine and half-dose CMG (Cytarabine+ Mitoxantrone+G-CSF) in Patients with refractory/relapsed acute myeloid leukemia (AML) previously exposed to Venetoclax: a single-center retrospective study.
Leuk Res Rep
June 2025
Department of Hematology, The Second Hospital of Hebei Medical University, No. 215, Heping West Road, Shijiazhuang, Hebei, 050000, China.